Digital therapeutics and virtual care provider Biofourmis surpassed a $1 billion valuation when it closed a $300 million series D funding round April 26.
Artificial intelligence in healthcare “doesn’t really exist right now,” even though it should, according to Aike Ho, a partner at venture capital firm Acme Capital.
Algorithms used to estimate risk of heart problems are performing poorly when applied to new populations, resulting in substantial risk of harm, according to a study published in Circulation April 5.
U.S. digital health funding reached $6 billion across 183 deals in the first quarter of 2022, falling behind the $7.3 billion raised in the fourth quarter of 2021, according to Rock Health’s quarterly report.
Anthem, Biogen, Eli Lilly, Evidation, Janssen, Merck, Pfizer and Savvy Co-op partnered with a nonprofit organization to develop a toolkit to support reimbursement for new drugs developed using digital endpoints.